← Back to patent-cliff list
CU-06
Tier C — Watch / tradeCU-06
Curacle Co Ltd
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：PT, VEGF, IL1B
Indications (approved)：Diabetic macular oedema, Ulcerative colitis, Lung disease, Crohn's disease, 年龄相关性黄斑变性, Diabetic retinopathy, Myocardial infarction, 遗传性血管性水肿
Regional status
US
Phase II
2022-12-21
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of CU-06?
Approved indications include: Diabetic macular oedema, Ulcerative colitis, Lung disease, Crohn's disease, 年龄相关性黄斑变性, Diabetic retinopathy, Myocardial infarction, 遗传性血管性水肿.
When does the CU-06 patent expire?
No public expiry year is available for CU-06 yet; this page updates once verified.
How do I get a quote for CU-06 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-03